Search

Displaying results 2091 - 2100 of 8411 in total
  1. Drug

    Shark liver oil

    go.drugbank.com/drugs/DB11088
    Approved

    Shark oil is extracted from the livers of sharks, which can account for up to 25% of their total body weight. … The potential benefit of shark oil has been experimented in different therapeutic implications, where it is claimed to improve immune responses and exert an antitumor activity.

    Mixtures: DG Health Hemorrhoidal
  2. Drug

    Antrafenine

    go.drugbank.com/drugs/DB01419
    Approved

    Antrafenine is a piperazine derivative drug that acts as an analgesic and anti-inflammatory drug with similar efficacy to naproxen.

  3. Drug

    Technetium Tc-99m exametazime

    go.drugbank.com/drugs/DB09163
    Approved

    It can also be used for the labelling of leukocytes to localise intra-abdominal infections and inflammatory bowel disease.

  4. Drug

    Nefazodone

    go.drugbank.com/drugs/DB01149
    ApprovedWithdrawn

    Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. … Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb.

    Categories: P-glycoprotein inducers, P-glycoprotein inhibitors
  5. Drug

    Celecoxib

    go.drugbank.com/drugs/DB00482
    ApprovedInvestigational

    Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptom...

    Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesSynonyms: p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
  6. Drug

    Levacetylmethadol

    go.drugbank.com/drugs/DB01227
    ApprovedWithdrawn

    Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well.[L44052,T862]

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  7. Drug

    PF-06260414

    go.drugbank.com/drugs/DB15221
    Investigational

    PF-06260414 is under investigation in clinical trial NCT02070939 (Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects

  8. Drug

    Tridihexethyl

    go.drugbank.com/drugs/DB00505
    ApprovedWithdrawn

    Tridihexethyl is an antimuscarinic, anticholinergic drug. Tridihexethyl is no longer available in the US market.

  9. Drug

    PF-232798

    go.drugbank.com/drugs/DB14813
    Investigational

    PF-232798 is under investigation in clinical trial NCT01140425 (Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects).

    Synonyms: PF-00232798
  10. Target

    Malate dehydrogenase, cytoplasmic

    go.drugbank.com/bio_entities/BE0000589
    TargetHumans

    Catalyzes the reduction of aromatic alpha-keto acids in the presence of NADH (PubMed:2449162, PubMed:3052244). Plays essential roles in the malate-aspartate shuttle and the tricarboxylic acid cycle, important in mitochondrial NADH supply...

    Synonyms: KAR